Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
2023 Interim Report | The next city is hard to find. How should Jiu'an Healthcare, which has 3 billion dollars in cash, spend money?
Invest
NASH testing works on a pay-per-use basis, and Furui shares surged 19% | Insight Research
The next 10 billion dollar market - NASH
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning
2023 Interim Report | Aibo Medical is increasing optometry and evasion and wants to launch the GDR to hit overseas markets?
Lustful and honest
Jimin Healthcare opens up a corner of high-end healthcare for the rich
A corner of the rich high-end healthcare industry is being interpreted by Jimin Healthcare (603222.SH). On July 25, the financial report released by Jimin Medical showed that revenue for the first half of 2023 was 444 million yuan, an increase of 1.64% over the previous year, while the net profit for the same period was 39 million yuan, down 39.50% from the previous year. The key reason for this sharp decline in profits points to the slump in exports of syringes, one of Jimin Medical's core products. “Mainly due to the decline in the company's exports of safe syringes (needles). The number of safe syringes (needles) exported by the company during the reporting period decreased by 73.33% compared with the same period last year